Navigation Links
More pain means real gain in complex regional pain syndrome treatment
Date:11/12/2009

Los Angeles, London, New Delhi, Singapore and Washington DC (November 12, 2009) The saying "more pain, more gain" may be true for those already in terrible pain due to a chronic and debilitating condition, contrary to received wisdom. For those with Type I Complex Regional Pain Syndrome (CRPS), working through the pain of an aggressive physiotherapy program often leads to far better results than a more cautious pain-free approach. That was the result of a new study in Clinical Rehabilitation, published this week by SAGE. In fact, nearly half those who were given the painful treatment recovered normal physical function, whereas those who avoided painful physiotherapy usually had further loss of physical function.

CRPS is a chronic progressive disease characterized by severe pain, swelling and changes in the skin. The cause of this syndrome is currently unknown. Although CRPS may follow injury and surgery, this is not always the case.

Jan-Willem Ek, Jan C van Gijn and colleagues from the Department of Rehabilitation Medicine at Bethesda Hospital in The Netherlands studied 106 patents suffering severe physical impairments from CRPS Type I, which does not involve nerve lesions (unlike Type II). They found that almost all the patients improved significantly when subjected to a rehabilitation program involving graded pain exposure. In fact, more than half the patients in the study recovered full physical movement, and none of the patients experienced adverse effects from this more aggressive approach. While this "full on" approach doesn't reduce the amount of pain associated with the condition, it does provide sufferers with a significant increase in mobility, function and quality of life. Traditional treatments for this chronic condition typically minimize the pain, which limits physiotherapy significantly and usually leads to greater deterioration of the affected limb.

CPRS can vary from joint stiffness and moderate pain in the arms or legs to paralysis and complete loss of function in more extreme cases. People suffering from this condition usually have a poor prognosis. That's because the condition often leads to extensive changes in the brain itself, making treatment to the affected limb almost ineffective. Given that the brain is usually affected in this chronic condition, it's almost impossible to reduce the pain of this disease by trying to treat the isolated limb. The result is a vicious circle, where the pain of the condition limits the amount of therapy, which in turn causes more deterioration in the limb and the brain, which further hampers any recovery.

Typically, physicians resist therapies where excessive levels of pain are involved, for fear of causing further injuries to the arm or leg. However, the habitual pain from CRPS Type I is often a false warning sign. This seriously limits the extent of therapy that's offered, and often precludes the more aggressive treatments like traction, stretching and massage. Often, the result is that people's joints begin to deteriorate even faster.

"In our experience one of the cornerstones of the success of pain exposure physical therapy is to motivate the patient to undergo both the painful interventions and to keep training and exercising at home," says one of the co-authors, Robert van Dongen. This new insight into this debilitating condition allows doctors and physiotherapists to provide patients with hope for a more functional and normal life.


'/>"/>

Contact: Mithu Lucraft
mithu.lucraft@sagepub.co.uk
44-207-324-2223
SAGE Publications UK
Source:Eurekalert

Related biology news :

1. Less Arctic ice means higher risks, experts warn
2. Bad news for coastal ocean: less fish out, means more nitrogen in
3. Scientists demonstrate means of reducing Alzheimers-like plaques in fly brain
4. Researchers devise means to create blood by identifying earliest stem cells
5. Shorter wait means longer life for kidney transplant candidates
6. Self-digestion as a means of survival
7. Redefining what it means to be a prion
8. Study validates means to measure possible leukemia marker
9. Purple sweet potato means increased amount of anti-cancer components
10. Warmer environment means shorter lives for cold-blooded animals
11. K-State geographer working to clarify what sustainability really means to rural decision-makers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/2/2016)... , Feb. 2, 2016   Parabon NanoLabs ... the U.S. Army Research Office and the Defense ... and sensitivity of the company,s Snapshot Kinship ... Mission and, more generally, defense-related DNA forensics.  Although ... capabilities (predicting appearance and ancestry from DNA evidence), ...
(Date:2/1/2016)... YORK , Feb. 1, 2016  Today, the ... Association (AHA) announced plans to develop a first of ... computing power of IBM Watson. In the first application ... AHA, IBM (NYSE: IBM ), and Welltok will ... and health assessments with cognitive analytics, delivered on Welltok,s ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... 2016 - New FDA action date of ... FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast has ... indicated for the treatment of signs and symptoms of dry eye ... potential to be the only product approved in the U.S. in the past decade indicated ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Investor Conference 2016, to be held February 8-9, 2016, ... Group,s 2016 Disruptive Growth & Healthcare Conference, taking place ... 10-11, 2016. James Sapirstein , Chief Executive ...
(Date:2/4/2016)... 4, 2016 Strasbourg, France ... --> Strasbourg, France , to the ... PharmaVentures is pleased to announce that it acted as an ... unit in Strasbourg, France , to the ... --> --> Transgene (Euronext: TNG), a member ...
Breaking Biology Technology: